PMID- 34734431
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20220420
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 47
IP  - 4
DP  - 2022 Apr
TI  - The efficacy and safety of immune checkpoint inhibitor in patients with relapsed 
      small-cell lung cancer: A systematic review and meta-analysis.
PG  - 421-429
LID - 10.1111/jcpt.13552 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) have been 
      approved for treating small-cell lung cancer (SCLC). However, the efficacy and 
      safety profile of ICIs for relapsed SCLC remains under investigation. In this 
      study, we assessed the efficacy and safety of ICIs in the treatment of relapsed 
      SCLC patients. METHODS: The databases, including Pubmed, Embase, and the Cochrane 
      library, were systematically searched to retrieve potential eligible studies from 
      the establishment of the database to May 2021. The primary outcomes were 
      survival, treatment responses, and safety. Randomized controlled trials and 
      real-world studies that met the inclusion criteria were included. The RevMan 5.4 
      and R software were used for meta-analysis. RESULTS AND DISCUSSION: A total of 
      eight articles involving 653 patients was included. Meta-analyses results showed 
      that the overall response rate (objective response rate [ORR]) of the ICIs group 
      was 0.12 (95% confidence interval [CI]: 0.07-0.18). The median overall survival 
      was 7.97 (95% CI: 5.94-9.47) months, while the progression-free survival was 1.70 
      (95% CI: 1.40-2.28) months. Although chemotherapy showed a favourable ORR (odds 
      ratio [OR] = 0.74; 95% CI: 0.39-1.41; p = 0.36) and a significantly better 
      disease control rate (OR = 0.28; 95% CI: 0.11-0.70; p = 0.007), patients treated 
      with ICIs had a reduced risk of mortality (hazard ratio = 0.87; 95% CI: 
      0.73-1.03; p = 0.10). With regards to adverse events (AEs), the rates of any AEs 
      and >/=grade 3 AEs were 0.56 (95% CI: 0.52-0.60) and 0.13 (95%CI: 0.06-0.20), 
      respectively. WHAT IS NEW AND CONCLUSION: For relapsed SCLC patients, the 
      administration of ICIs resulted in a similar survival outcome and acceptable 
      safety compared with chemotherapy. Further studies are needed to explore 
      potential biomarkers for relapsed SCLC patients who may benefit from 
      immunotherapy.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Xu, Yulian
AU  - Xu Y
AUID- ORCID: 0000-0003-0608-544X
AD  - Department of Oncology, Zaoyang First People's Hospital, Xiangyang, Hubei, China.
FAU - Chen, Mingxian
AU  - Chen M
AD  - Department of Oncology, Zaoyang First People's Hospital, Xiangyang, Hubei, China.
FAU - Ding, Yanpeng
AU  - Ding Y
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, Hubei, China.
FAU - Guo, Feng
AU  - Guo F
AD  - Department of Oncology, Zaoyang First People's Hospital, Xiangyang, Hubei, China.
FAU - Chen, Min
AU  - Chen M
AD  - Department of Gynecology, Zaoyang First People's Hospital, Xiangyang, Hubei, 
      China.
FAU - Lu, Tianzhen
AU  - Lu T
AD  - Department of Gastroenterology, Zaoyang First People's Hospital, Xiangyang, 
      Hubei, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20211103
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Lung Neoplasms/drug therapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Progression-Free Survival
MH  - *Small Cell Lung Carcinoma/drug therapy
OTO - NOTNLM
OT  - immune checkpoint inhibitor
OT  - meta-analysis
OT  - relapsed
OT  - small-cell lung cancer
OT  - survival
EDAT- 2021/11/05 06:00
MHDA- 2022/04/21 06:00
CRDT- 2021/11/04 06:41
PHST- 2021/10/13 00:00 [revised]
PHST- 2021/08/26 00:00 [received]
PHST- 2021/10/17 00:00 [accepted]
PHST- 2021/11/05 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
PHST- 2021/11/04 06:41 [entrez]
AID - 10.1111/jcpt.13552 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2022 Apr;47(4):421-429. doi: 10.1111/jcpt.13552. Epub 2021 Nov 
      3.